HAEMATOLOGY

Clinical Trials 

Click on button to go to trial details:

  ALL TRIALS   ALL5  

  AML TRIALS  AML17   RICT IN AML      

  CLL TRIALS  CONTINUUM   OFOCIR - CLL5   ORIGIN - CLL008   ROCHE - CLL11

  CML TRIALS   NO CURRENT TRIALS

  ITP        R-100

  MYELOMA TRIALS   NO CURRENT TRIALS

  NHL TRIALS   BRIGHT    ROCHE FOLLICULAR LYMPHOMA SC

  PNH TRIALS   PNH

  SUPPORTIVE CARE  POSACONAZOLE   TELESTO

  THROMBOCYTHAEMIA TRIALS   PT1   

  TRANSPLANT TRIALS   ZOMETA  

                                                          CLICK HERE FOR ADVERSE EVENTS GRADING                                                                   

Acronym Study Title Ethics Reference Principle Investigator Trial
Co-ordinator		 Study Status
ACUTE LYMPHOBLASTIC LEUKAEMIA        

ALL5
(Dasatinib for Ph+ ALL)
 		 A PHASE II STUDY OF DASATINIB COMBINED WITH INDUCTION  CHEMOTHERAPY IN PREVIOUSLY UNTREATED DE NOVO PHILADELPHIA + ACUTE LYMPHOBLASTIC LEUKAEMIA   Dr Andrew Butler Jo Sanders open to accrual
ACUTE MYELOID LEUKAEMIA        
 AML17 AML17 IS A RANDOMISED, CONTROLLED, OPEN LABEL PHASE III TRIAL FOR PATIENTS WITH AML AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) MEC/09/11/120 Dr Ruth Spearing Jo Sanders open to accrual
RICT IN AML allo stem cell transplantation with reduced conditioning (RICT) versus best standard of care in AML in first complete remission. 
PROTOCOL NUMBER: TRALG1/02		 URB/
06/06/043		 Dr Ruth Spearing Jo Sanders open to accrual
CHRONIC LYMPHOCYTIC LEUKAEMIA        

CONTINUUM
(Lenalidomide for CLL maintenance)		 A PHASE 3, MULTICENTRE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CLL FOLLOWING SECOND-LINE THERAPY.
PROTOCOL NUMBER: CC-5013-CLL-002		   Dr Steve Gibbons Jo Sanders open to accrual

OFOCIR - CLL5
(First line therapy FCR 65+)

 

 A RANDOMIZED, OPEN-LABEL MULTICENTRE, PHASE2/3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUMILIXIMAB IN COMBINATION WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB ALONE IN SUBJECTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA.   Dr Peter Ganly Jo Sanders open to accrual
ORIGIN -CLL008

 

 A PHASE 3, MULTICENTRE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) VERSUS CHLORAMBUCIL AS FIRST LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA.
PROTOCOL NO. CC-5013-CLL-008		   Dr Steve Gibbons Jo Sanders open to accrual
 ROCHE - CLL11 AN OPEN-LABEL, MULTI-CENTRE, THREE ARM RANDOMISED, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF RO5072759 + CHLORAMBUCIL (GClb), RITUXIMAB + CHLORAMBUCIL (RClb) OR CHLORAMBUCIL (Clb) ALONE IN PREVIOUSLY UNTREATED CLL PATIENTS NOT ELIGIBLE FOR FLUDARABINE-BASED CHEMOIMMUNOTHERAPY.
PROTOCOL NO:CLL11 (B021004D)		   Dr Andrew Butler Jo Sanders open to accrual
CHRONIC MYELOID LEUKAEMIA   NO CURRENT TRIALS      
IDIOPATHIC THROMBOCYTOPENIC PURPURA        
R-100 A MULTI-CENTRE, SINGLE ARM, PHASE II STUDY TO EVALUATE THE EFFICACY OF A WEEKLY 100MG DOSE OF RITUXIMAB OVER FOUR WEEKS IN PATIENTS WITH REFRACTORY OR RELAPSING IDIOPATHIC THROMBOCYTOPENIC PURPURA (THE R-100 ITP STUDY) MEC/09/02/018 Dr Ruth Spearing Jo Sanders open to accrual
MULTIPLE MYELOMA   NO CURRENT TRIALS        

NON-HODGKIN'S LYMPHOMA

       

BRIGHT
(Indolent NHL)		 AN OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP STUDY OF BENDAMUSTINE HYDROCHLORIDE AND RITUXIMAB (BR) COMPARED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE (R-CVP) OR RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (R-CHOP) IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA (NHL) OR MANTLE CELL LYMPHOMA (MCL).
PROTOCOL NUMBER: C18083/3064/NL/MN		   Dr Peter Ganly
 		 Jo Sanders open to accrual
ROCHE FOLLICULAR LYMPHOMA SC A TWO-STAGE PHASE III, INTERNATIONAL , MULTI-CENTRE, RANDOMISED, CONTROLLED, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY AND SAFETY OF RITUXIMAB SC IN COMBINATION WITH CHOP OR CVP VERSUS RITUXIMAB IV IN COMBINATION WITH CHOP OR CVP IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA FOLLOWED BY MAINTENANCE TREATMENT WITH EITHER RITUXIMAB SC OR RITUXIMAB IV.
PROTOCOL NUMBER:
B022334/A		 MEC/10/09/098 Dr Andrew Butler Helen McDermott open to accrual
PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA        
PNH  OBSERVATIONAL REGISTRY COMPILING DATA ON THE HISTORY AND MANAGEMENT OF PATIENTS DIAGNOSED WITH PNH URA/
06/02/001		 Dr Ruth Spearing Jo Sanders open to accrual
PRIMARY THROMBOCYTHAEMIA        
PT1  A RANDOMISED TRIAL TO COMPARE ASPIRIN VERSUS HYDROXYUREA/ASPIRIN IN 'INTERMEDIATE RISK' PT AND ASPIRIN ONLY WITH OBSERVATION IN 'LOW RISK' PT
PROTOCOL NUMBER: PT1		 00/11/157 Dr Steve Gibbons Jo Sanders open to accrual
SUPPORTIVE CARE        

POSACONAZOLE

 

 PHARMACOKINETICS AND SAFETY OF SOLID ORAL POSACONAZOLE (SCH56592) IN SUBJECTS AT HIGH RISK FOR INVASIVE FUNGAL INFECTIONS (PHASE 1B)
PROTOCOL No. P05615		   Dr Liam Fernyhough Jo Sanders open to accrual
 

 TELESTO

 

 A MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) AND TRANSFUSIONAL IRON OVERLOAD (TELESTO)
PROTOCOL NUMBER: CICL670A2302		   Dr Ruth Spearing Jo Sanders open to accrual
TRANSPLANT         

ZOMETA
(Post Allo SCT)		 A TREATMENT ALGORITHM EVALUATING THE EFFECT OF ZOLEDRONIC ACID ON BONE MINERAL DENSITY LOSS AFTER ALLOGENIC STEM CELL TRANSPLANTATION. MEC/09/02/010 Dr Peter Ganly Jo Sanders open to accrual